Investigating the safety of CAN10 antibody in healthy individuals and those with plaque psoriasis

A Phase I (First-in-human) Randomized, Double-blind, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CAN10, an Anti-IL1RAP Monoclonal Antibody, in Healthy Subjects and in Subjects With Mild to Moderate Plaque Psoriasis.

This study is testing the safety of a new antibody called CAN10 in healthy people and those with mild to moderate plaque psoriasis to see how well they tolerate it and how it works in their bodies.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Ages: 18 Years to 50 Years
• Sex: All
• Sponsor: Cantargia AB (Industry-sponsored)
• Drugs / interventions: methotrexate
• Locations: 1 site (Berlin)
• Trial ID: NCT06143371 on ClinicalTrials.gov

What this trial studies

This is a first-in-human, randomized, double-blind, placebo-controlled, dose escalation study designed to evaluate the safety and tolerability of the CAN10 antibody. The study consists of two parts: the first part involves administering a single intravenous dose of CAN10 to healthy subjects, while the second part involves giving multiple subcutaneous doses to participants with mild to moderate plaque psoriasis. The study aims to assess how different doses are tolerated, how the body absorbs CAN10, and the duration it remains in the body.

Who should consider this trial

Good fit: Ideal candidates include healthy adults aged 18 to 50 and individuals with mild to moderate plaque psoriasis.

Not a fit: Patients with severe plaque psoriasis or those outside the specified age and health criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to a new treatment option for patients with plaque psoriasis.

How similar studies have performed: Other studies investigating similar monoclonal antibodies have shown promise, suggesting potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

* Male or female, aged 18 to 50 years of age (inclusive) at the time of signing informed consent.
* Body mass index (BMI) 18 to 30 kg/m2 (inclusive) and a weight between 50 to 100 kg (inclusive) at the time of screening
* Considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at screening.
* Female subjects of childbearing potential must use a highly effective method of birth control and have a negative pregnancy test at screening and before the first dose of study drug. Male subjects with female partners must agree to use a condom, and their female partners are recommended to use a highly effective method of birth control.

Additionally for subjects with plaque psoriasis only:

* A diagnosis of plaque psoriasis with Psoriasis Area Severity Index (PASI) score ≥3 to ≤15 and Physician Global Assessment (PGA) score ≥2 (mild) to \<4 (moderate).
* No disease manifestation requiring systemic immunosuppressive therapy.

Exclusion Criteria:

* History or presence of:

  1. Severe allergy/hypersensitivity (subjects with mild pollen allergy can be included).
  2. Significant kidney, liver, or urologic disease.
  3. Clinically significant psychiatric disorders
  4. Tuberculosis (TB) infection or positive QuantiFERON TB Gold test
  5. Any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
* Clinically significant illness, medical/surgical procedure, or trauma within 4 weeks before the first dose of study drug.
* Ongoing opportunistic or systemic infections
* A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus antigen or antibodies at screening.

Additionally for subjects with plaque psoriasis only:

* Psoriasis other than a plaque variant.
* Any sign of infection of any of the psoriatic lesions.
* Use of any of the following treatments within the indicated washout period before the first dose of study drug:

  1. 12 weeks or 5 half-lives (whichever is longer) for biologic agents known or expected to impact the course of psoriasis or its assessments.
  2. 12 weeks for oral retinoids
  3. 8 weeks for cyclosporin, interferon, methotrexate, other systemic immunosuppressive or immunomodulating agents, or psoralen plus ultraviolet A (UVA)
  4. 2 weeks for immunizations or drugs known to possibly worsen psoriasis, unless on a stable dose for \>12 weeks
  5. 1 week for topical treatments: corticosteroids, immunomodulators, anthralin (dithranol), Vitamin D derivatives, retinoids, or coal tar (used on the body)

Where this trial is running

Berlin

• CRS Clinical Research Services Berlin GmbH — Berlin, Germany (Recruiting)

Study contacts

• Principal investigator: Manuela Casjens, MD — CRS Clinical Research Services Berlin GmbH
• Study coordinator: Cantargia Ab

Conditions Healthy; Plaque Psoriasis